D. E. Shaw & Co. Inc. Buys 695,950 Shares of Horizon Therapeutics PLC (NASDAQ:HZNP)

Share on StockTwits

D. E. Shaw & Co. Inc. lifted its stake in shares of Horizon Therapeutics PLC (NASDAQ:HZNP) by 15.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,097,929 shares of the biopharmaceutical company’s stock after purchasing an additional 695,950 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Horizon Therapeutics were worth $122,656,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. Renaissance Technologies LLC grew its holdings in shares of Horizon Therapeutics by 11.4% during the 2nd quarter. Renaissance Technologies LLC now owns 8,754,275 shares of the biopharmaceutical company’s stock valued at $210,628,000 after purchasing an additional 896,500 shares during the last quarter. William Blair Investment Management LLC grew its holdings in shares of Horizon Therapeutics by 4.0% during the 1st quarter. William Blair Investment Management LLC now owns 6,942,357 shares of the biopharmaceutical company’s stock valued at $183,486,000 after purchasing an additional 269,565 shares during the last quarter. FMR LLC grew its holdings in shares of Horizon Therapeutics by 165.1% during the 1st quarter. FMR LLC now owns 5,205,217 shares of the biopharmaceutical company’s stock valued at $137,575,000 after purchasing an additional 3,242,071 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Horizon Therapeutics by 14.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,090,627 shares of the biopharmaceutical company’s stock valued at $122,480,000 after purchasing an additional 657,459 shares during the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of Horizon Therapeutics by 7.6% during the 2nd quarter. Jennison Associates LLC now owns 2,370,618 shares of the biopharmaceutical company’s stock valued at $57,037,000 after purchasing an additional 167,929 shares during the last quarter. 86.28% of the stock is currently owned by institutional investors.

HZNP traded up $0.77 during trading on Friday, reaching $27.27. 1,025,349 shares of the company’s stock were exchanged, compared to its average volume of 880,548. The stock has a market capitalization of $4.92 billion, a PE ratio of 14.90, a price-to-earnings-growth ratio of 1.55 and a beta of 0.77. Horizon Therapeutics PLC has a one year low of $16.56 and a one year high of $29.44. The company has a current ratio of 2.20, a quick ratio of 2.12 and a debt-to-equity ratio of 0.90. The firm has a fifty day moving average price of $26.67 and a two-hundred day moving average price of $25.71.

Horizon Therapeutics (NASDAQ:HZNP) last issued its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.14. Horizon Therapeutics had a net margin of 5.90% and a return on equity of 30.33%. The firm had revenue of $320.60 million for the quarter, compared to the consensus estimate of $296.27 million. During the same quarter in the previous year, the company earned $0.48 EPS. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Sell-side analysts expect that Horizon Therapeutics PLC will post 1.6 earnings per share for the current year.

In related news, EVP Vikram Karnani sold 13,111 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $25.02, for a total transaction of $328,037.22. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Chairman Timothy P. Walbert sold 58,820 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $28.00, for a total transaction of $1,646,960.00. The disclosure for this sale can be found here. Insiders have sold a total of 268,616 shares of company stock worth $7,361,526 in the last quarter. 4.10% of the stock is owned by corporate insiders.

HZNP has been the topic of several research reports. Piper Jaffray Companies set a $33.00 price target on shares of Horizon Therapeutics and gave the company a “buy” rating in a report on Monday, August 26th. Cowen set a $35.00 target price on shares of Horizon Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 7th. ValuEngine lowered shares of Horizon Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 5th. BidaskClub lowered shares of Horizon Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 6th. Finally, Stifel Nicolaus set a $35.00 target price on shares of Horizon Therapeutics and gave the stock a “buy” rating in a report on Friday, September 13th. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $33.00.

Horizon Therapeutics Company Profile

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Recommended Story: What are some reasons analysts would give stocks a buy rating?

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Therapeutics (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ubex  Price Hits $0.0004
Ubex Price Hits $0.0004
Maximine Coin 1-Day Trading Volume Tops $43,578.00
Maximine Coin 1-Day Trading Volume Tops $43,578.00
Coupa Software Inc  Expected to Announce Quarterly Sales of $96.52 Million
Coupa Software Inc Expected to Announce Quarterly Sales of $96.52 Million
PAXEX  Price Tops $0.0002
PAXEX Price Tops $0.0002
ZCore One Day Trading Volume Tops $1,202.00
ZCore One Day Trading Volume Tops $1,202.00
Brokerages Set $67.00 Target Price for Neenah Inc
Brokerages Set $67.00 Target Price for Neenah Inc


© 2006-2019 Ticker Report